• Publications
  • Influence
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
  • Y. Shi, M. Dong, +15 authors X. Lu
  • Medicine
  • Annals of oncology : official journal of the…
  • 1 August 2015
BACKGROUND Chidamide is a novel benzamide type of subtype-selective histone deacetylase (HDAC) inhibitor with unique mechanisms of action compared with marketed HDAC inhibitors. This phase II studyExpand
Randomized phase III study 306
Objective: To evaluate the efficacy and safety of perampanel 2, 4, and 8 mg/day added to 1–3 concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial-onset seizures. Methods:Expand
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
  • W. Yong, B. Goh, +11 authors J. Zhu
  • Medicine
  • Annals of oncology : official journal of the…
  • 1 November 2011
BACKGROUND The objective of this study was to assess the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SB939, a novel histone deacetylaseExpand
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
Background:SB939 is an orally available, competitive histone deacetylase (HDAC) inhibitor selective for class I, II and IV histone deacetylases. Preclinical evaluation of SB939 revealed a profileExpand
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma
tions are associated with treatment resistance in other cancers, the functional effect of this deletion has not been characterized. Conclusions: DLBCL patients with mutations in relapse-enrichedExpand
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
The consensus statements regarding first-line therapies in women with ovarian cancer, reached at the Fifth Ovarian Cancer Consensus Conference held in Tokyo, Japan, in November 2015 are reported.Expand
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial
Background Patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) ≥3 are at higher risk for relapse after a complete response (CR) to first-lineExpand
SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.
4500 Background: SU011248 is an oral multi-targeted tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity through inhibition of PDGFR, VEGFR, KIT and FLT3. METHODS 63 patients withExpand
The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma.
  • C. Qin, Q. Cao, +11 authors Z. Zhang
  • Medicine
  • Annals of oncology : official journal of the…
  • 1 April 2012
BACKGROUND The von Hippel-Lindau (VHL) tumor suppressor gene and hypoxia-inducible factor-1α (HIF1A) play a pivotal role in renal carcinogenesis. This study was aimed to clarify the influence of VHLExpand
Association of IL‐4 −590 T>C polymorphism and risk of renal cell carcinoma in a Chinese population
  • J. Zhu, X. Ju, +5 authors C. Yin
  • Biology, Medicine
  • International journal of immunogenetics
  • 1 December 2010
Interleukin 4 (IL‐4) is a typical pleiotropic T helper 2 (Th2) cytokine. This cytokine is a critical mediator of the Th1/Th2 balance and apoptosis potential and involved in the process ofExpand